Abstract
Purpose. The goal of this study was to find a rational and reliable method of using animal data to predict the clearance of metabolised drugs in humans.
Methods. One such approach is to use in vitro liver models (e.g. hepatocytes and microsomes) to determine the relative capacities of the various animal species and humans to metabolise the test compound. These data can then be combined with the in vivo clearances in animals, to calculate the in vivo clearance in humans using allometric scaling techniques. In this study, this approach was evaluated with a new endothelin receptor antagonist, bosentan, which is eliminated mainly through metabolism and is characterized by very large interspecies differences in clearance. Therefore, this compound provided a stringent test of our new extrapolation method for allometric scaling.
Results. The results obtained with bosentan showed that adjusting the in vivo clearance in the different animal species for the relative rates of metabolism in vitro gave a far better prediction of human clearance than an empirical correcting factor (brain weight).
Conclusions. This approach provided a more rational basis for predicting the clearance of metabolised compounds in humans.
Similar content being viewed by others
REFERENCES
Y. Sawada, M. Hanano, Y. Sugiyama, and T. Iga. Prediction of the disposition of beta-lactam antibiotics in humans from pharmacokinetic parameters in animals. J. Pharmacokinet. Biopharm. 12:241–61 (1984).
B. Boxenbaum, and R. W. D'Souza. Interspecies Pharmacokinetic Scaling, Biological Design and Neoteny. In B. Testa (eds.), Advances in Drug Research, Academic Press Limited, London, 1990, pp. 139–196.
P. J. McNamara. Interspecies scaling in pharmacokinetics. In P. G. Welling, F. L. S. Tse and S. V. Dighe (eds.), Pharmaceutical bioequivalence, Marcel Dekker, New York, 1991, pp. 267–300.
D. B. Campbell. Can allometric interspecies scaling be used to predict human kinetics. Drug Inf. J. 28:235–245 (1994).
H. Boxenbaum, and J. B. Fertig. Scaling of antipyrine intrinsic clearance of unbound drug in 15 mammalian species. Eur. J. Drug Metab. Pharmacokinet. 9:177–83 (1984).
T. Lave, A. H. Schmitt-Hoffmann, P. Coassolo, G. Ubeaud, B. Vallès, B. Ba, R. Brandt, and R. C. Chou. A new extrapolation method from animal to man; application to a metabolized compound, mofarotene. Life Sci. 56:473–478 (1995).
C. Von Bahr, C.-G. Groth, H. Jansson, G. Lundgren, M. Lind, and H. Glaumann. Drug metabolism in human liver in vitro: Establishment of a human liver bank. Clin. Pharm. Ther. 27:711–725 (1980).
P. O. Seglen. Preparation of isolated rat liver cells. Meth. Cell Biol. 13:29–83 (1976).
T. Seddon, I. Michelle, and R. J. Chenery. Comparative drug metabolism of diazepam in hepatocytes isolated from man, rat, monkey and dog. Biochem. Pharmacol. 38:1657–1665 (1989).
J. Mordenti. Man versus beast: pharmacokinetic scaling in mammals. J. Pharm. Sci. 75:1028–40 (1986).
J. B. Houston. Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. Biochem. Pharmacol. 47:1469–1479 (1994).
K. S. Pang, P. Kong, J. A. Terrell, and R. E. Billings. Metabolism of acetaminophen and phenacetin by isolated rat hepatocytes. A system in which the spatial organization inherent in the liver is disrupted. Drug Metab. Dispos. 13:42–50 (1985).
A. Rane, G. R. Wilkinson, and D. G. Shand. Prediction of hepatic extraction ratio from in vitro measurement of intrinsic clearance. J. Pharmacol. Exp. Ther. 200:420–4 (1977).
B. A. Hoener. Predicting the hepatic clearance of xenobiotics in humans from in vitro data. Biopharm. Drug Dispos. 15:295–304 (1994).
C. Bäärnhielm, H. Dählback, and I. Skanberg. In vivo pharmacokinetics of felodipine predicted from in vitro studies in rat, dog and man. Acta Pharm. Toxicol. 59:113–22 (1986).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Lave, T., Coassolo, P., Ubeaud, G. et al. Interspecies Scaling of Bosentan, A New Endothelin Receptor Antagonist and Integration of in Vitro Data into Allometric Scaling. Pharm Res 13, 97–101 (1996). https://doi.org/10.1023/A:1016037519116
Issue Date:
DOI: https://doi.org/10.1023/A:1016037519116